The price of Ozempic is a meaningless phrase

By JOHN SAMARAS Ask what Ozempic costs. The honest answer runs from $25 a month to $1,100 a month, and every number in that range is real, published, and defensible. A phrase that covers a forty-four-fold spread is not a price. It is a fog, and patients make four-figure annual decisions inside it. I run…

Read More

Physician Competition: Entry and Substitution

That is the title of a Journal of Economic Literature article by Gottlieb and Nicholson (2026). Here is a Q&A summary of their article. What are the defining features of physician competition? The authors argue that competition in the physician market is a two-stage process: “First, potential physicians compete to enter medical school and then…

Read More

Value Is in the Eye of the Beholder

By KIM BELLARD The most (unintentionally) amusing story I read this week was Tim Higgin’s Wall Street Journal article Alex Karp Is Saying What Every Angry CEO Is Thinking About AI. Dr. Karp (yes, he has a Ph.D.), co-founder and CEO of Palantir Technologies, is upset about how AI companies are using relationships with their…

Read More

The wrong people are scared of clinical AI

By CRAIG HAUBEN Ask anyone outside healthcare who resists clinical AI and you’ll get a confident answer. The older doctors. The ones who spent thirty years building expertise and now see a machine coming for it. The story writes itself, which should have been the first clue it was wrong. I’ve spent thirty years in…

Read More

Medicaid managed care: An Explainer

A paper by Mark Shepard and Jacob Wallace (2026) has a great overview of the Medicaid managed care program. The first question one may have is, how does Medicaid managed care differ from other forms of government procurement. “In standard public procurement—such as contracting for infrastructure projects—the government specifies desired services, solicits bids, selects winners,…

Read More